PubRank

Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.

PubWeight™: 1.54‹?› | Rank: Top 4%

🔗 View Article (PMID 24743399)

Published in Eur J Endocrinol on April 17, 2014

Authors

Dharshini Karuppiah1, Gaya Thanabalasingham1, Brian Shine1, Lai Mun Wang1, Gregory P Sadler1, Niki Karavitaki1, Ashley B Grossman2

Author Affiliations

1: Departments of EndocrinologyChemical PathologyCellular PathologyEndocrine SurgeryOxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.
2: Departments of EndocrinologyChemical PathologyCellular PathologyEndocrine SurgeryOxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK ashley.grossman@ocdem.ox.ac.uk.

Articles citing this ↘

Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol (2015) 0.83

The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep (2014) 0.81

Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer (2016) 0.78

Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma. Eur J Endocrinol (2014) 0.75

Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep (2015) 0.75